ArticleFrontiers in immunology2025
Baseline neuronal antibodies in patients with small cell lung cancer are not necessarily associated with post-immune checkpoint inhibitors neurotoxicities.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives: Autoantibodies against intracellular neuronal antigens (IC-Abs) can be found in neurologically asymptomatic patients with small cell lung cancer (SCLC) and have been proposed as a predictive biomarker for the development of post-immune checkpoint inhibitors (ICIs) neurotoxicities. The aim of this study was to prospectively evaluate the association of baseline neural antibodies with immune-related adverse events (irAEs) - including neurological irAEs (n-irAEs) - and oncological outcomes in patients with SCLC following ICI therapy. Methods: In this prospective cohort study, consecutive patients with SCLC eligible for treatment with ICI were assessed for the presence of IC-Abs with both indirect immunofluorescence (IIF) tissue-based assay (TBA) and line-blot and underwent baseline neurological evaluation prior to ICI initiation. Patients were longitudinally monitored for irAEs occurrence and oncological outcomes. Comparisons between groups, time-to-event and multivariable analyses were performed. Results: Fifty-six neurologically asymptomatic patients with SCLC (median age 70.5 years, 38% female) were included. Nineteen (34%) had IC-Abs prior to ICI-treatment (anti-Hu, n=7 [37%]; anti-Zic4, n=6 [32%]; anti-SOX1, n=3 [16%]; anti-SOX1 and anti-Zic4, n=2 [11%]; anti-Purkinje cerebellar cells, n=1 [5%]). Following ICI-treatment, two patients (3.6%) developed a n-irAE (one with baseline anti-Hu antibodies; one without baseline IC-Abs). The presence of baseline IC-Abs was not associated with an increased incidence of n-irAEs. However, anti-Hu antibody positivity was associated with an increased risk of irAEs of any type (OR 8.3; 95% CI, 1.22-56.54). A non-significant trend toward longer progression-free survival was observed in anti-Hu-positive patients (9.4 vs 5.7 months; p=0.10). Discussion: The presence of baseline IC-Abs may not be associated with the occurrence of post-ICI neurotoxicities in patients with SCLC. However, anti-Hu antibody positivity correlates with an increased risk of irAEs of any type. Larger studies are needed to assess the safety of ICI therapy in patients with SCLC harbouring neural antibodies and to investigate their potential role as predictive biomarkers of post-ICI neurotoxicities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.